DE60231997D1 - Orale pharmazeutische formulierung mit aktivkohle und ihre verwendung - Google Patents

Orale pharmazeutische formulierung mit aktivkohle und ihre verwendung

Info

Publication number
DE60231997D1
DE60231997D1 DE60231997T DE60231997T DE60231997D1 DE 60231997 D1 DE60231997 D1 DE 60231997D1 DE 60231997 T DE60231997 T DE 60231997T DE 60231997 T DE60231997 T DE 60231997T DE 60231997 D1 DE60231997 D1 DE 60231997D1
Authority
DE
Germany
Prior art keywords
active carbon
oral pharmaceutical
pharmaceutical formulation
starch
paste
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60231997T
Other languages
English (en)
Inventor
Decai Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE60231997D1 publication Critical patent/DE60231997D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60231997T 2001-09-13 2002-09-09 Orale pharmazeutische formulierung mit aktivkohle und ihre verwendung Expired - Lifetime DE60231997D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNB01128840XA CN1281217C (zh) 2001-09-13 2001-09-13 活性碳在制备治疗甲亢症的口服药物制剂中的应用
PCT/CN2002/000630 WO2003022292A1 (fr) 2001-09-13 2002-09-09 Formulation pharmaceutique orale contenant du charbon actif et utilisation de cette formulation

Publications (1)

Publication Number Publication Date
DE60231997D1 true DE60231997D1 (de) 2009-05-28

Family

ID=4668655

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60231997T Expired - Lifetime DE60231997D1 (de) 2001-09-13 2002-09-09 Orale pharmazeutische formulierung mit aktivkohle und ihre verwendung

Country Status (8)

Country Link
US (1) US20040265299A1 (de)
EP (1) EP1437140B1 (de)
JP (1) JP2005524604A (de)
CN (1) CN1281217C (de)
AT (1) ATE428432T1 (de)
DE (1) DE60231997D1 (de)
ES (1) ES2322041T3 (de)
WO (1) WO2003022292A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004112498A1 (en) * 2003-06-20 2004-12-29 Hill's Pet Nutrition, Inc. Methods for hyperthyroidism in a cat and composition comprising limited iodine
US8501223B2 (en) 2003-06-20 2013-08-06 Hill's Pet Nutrition, Inc. Methods for dietary management of cats to avoid hyperthyroidism
CN101868242B (zh) * 2007-11-23 2012-07-18 法莫隆登西斯股份公司 获得支气管舒张的方法和手段
JP5701971B2 (ja) * 2011-03-04 2015-04-15 株式会社クレハ 錠剤型の経口投与用組成物及びその製造方法
CN110151792A (zh) * 2019-06-06 2019-08-23 合肥元佑健康管理有限公司 一种治疗甲亢的中药方及其制备方法
WO2021134482A1 (en) * 2019-12-31 2021-07-08 Fresenius Medical Care Deutschland Gmbh Direct compressed activated carbon tablet formulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3642986A (en) * 1970-04-01 1972-02-15 William Arthur Welch Aspirin-charcoal compositions
US5554370A (en) * 1994-05-27 1996-09-10 Kureha Kagaku Kogyo Kabushiki Kaisha Method for the treatment of inflammatory bowel diseases

Also Published As

Publication number Publication date
WO2003022292A1 (fr) 2003-03-20
EP1437140A1 (de) 2004-07-14
EP1437140A4 (de) 2005-06-22
JP2005524604A (ja) 2005-08-18
CN1281217C (zh) 2006-10-25
EP1437140B1 (de) 2009-04-15
CN1406587A (zh) 2003-04-02
ES2322041T3 (es) 2009-06-16
US20040265299A1 (en) 2004-12-30
ATE428432T1 (de) 2009-05-15

Similar Documents

Publication Publication Date Title
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
IL161154A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
JP2003520232A5 (de)
HUP0203556A2 (hu) Oxkarbazepint tartalmazó gyógyszerkészítmények és alkalmazásuk
ATE313319T1 (de) Vorgelatinierte stärke in einer formulierung mit gesteuerter freigabe
MX9402938A (es) Composicion terapeutica que comprende nicotinamida-adenina-dinucleotido ynicotinamida-adenina-fosfato-dinucleotido, estable ingerible y absorbible.
DK0568577T3 (da) Peroralt indgivelig lægemiddelform til behandling af centrale dopaminmangeltilstande
CA2622805A1 (en) Compressed tablets comprising valsartan
BR9917012A (pt) Comprimido matricial, permitindo a liberação prolongada de gliclazida, após administração por via oral
ATE220321T1 (de) Feste flupirtin enthaltende orale darreichungsformen mit kontrollierter wirkstoffabgabe
CA2377174A1 (en) Oral administration forms for administering a fixed tramadol and diclofenac combination
NO992944L (no) Virkestoffbµrer for avgivelse av apomorfin i munnhulen
GEP20063882B (en) Dosage regimen and pharmaceutical composition for emergency contraception
RS44204A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
DK1104289T3 (da) Hidtil ukendte orale formuleringer for 5-HT4-agonister eller -antagonister
JP2001513506A5 (de)
DE60231997D1 (de) Orale pharmazeutische formulierung mit aktivkohle und ihre verwendung
ATE97572T1 (de) Azelastin enthaltende arzneimittel mit kontrollierter wirkstoffabgabe.
AU2003292006A1 (en) 3,5,3'-triiodothyronine sulfate as thyromimetic agent and pharmaceutical formulations thereof
NO954952L (no) Fremgangsmåte for fremstilling av en oral fast-stoff doseringsform som inneholder diklofenac
ATE331502T1 (de) 4-amino-1-hydroxybutyliden-1,1-biphosphonsäure enthaltende direktkomprimierte tablette
RS44304A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2001070184A3 (en) A composition containing monoterpenes for topical oral administration
ATE357220T1 (de) Pharmazeutische zusammensetzung mit modifizierter freisetzung
JPS6413019A (en) Aldose reductase inhibitor

Legal Events

Date Code Title Description
8364 No opposition during term of opposition